Drug Trial Radar · NCT05992077
Study of DAA Treatment for Children and Adolescents With Active HCV Infection in Cambodia
Last checked: Nov 19, 2026Latest source record: Dec 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
21,000
Planned (sponsor's estimate)
Start
Aug 7, 2023
Primary completion
Jan 31, 2026
Study completion Jan 31, 2026
Sponsor
- Lead sponsor
- ANRS, Emerging Infectious DiseasesGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- Collaborators
- Institute Pasteur, Cambodia
- First posted
- Aug 15, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 6 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate the effectiveness of sofosbuvir/daclatasvir combination for children aged ≥ 6 years old and adolescents with active HCV infection in Cambodia
Conditions
- HCV Infection
Interventions
Sofosbuvir/DaclatasvirDrug
Patients with a weight \> 25 kg will be treated with a sofosbuvir/daclatasvir combination for 12 weeks with adult dose (400/60 mg), children with a weight between 14 and 25 kg will be treated with the same sofosbuvir/daclatasvir combination with the half adult dose (200/30 mg) for 12 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluation of the effectiveness of sofosbuvir/daclatasvir combination for children aged ≥ 6 years old and adolescents with active HCV infection in CambodiaTime frame: 24 months
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Battambang Provincial Hospital
Battambang, Cambodia
Kantha Bopha Hospital
Phnom Penh, Cambodia
National Pediatric Hospital
Phnom Penh, Cambodia
Jayavarman VII Hospital
Siem Reap, Cambodia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.